AbbVie to buy ImmunoGen for $10.1 billion, boosting its oncology portfolio
AbbVie Inc. (NYSE: ABBV) announced today that it has agreed to acquire ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company focused on developing antibody-drug conjugates (ADCs)...
AbbVie Inc.
AbbVie Inc. is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. Traded as: NYSE: ABBV; S&P...